Objectives: The implantation of flow diverters, or stents in general, necessitates the use of dual anti-platelet treatment with typical regimes including aspirin and a P2Y12 inhibitor. This carries an inherent risk of haemorrhage. We sought to compare the thrombogenicity of the anti-thrombogenic p48 hydrophilic polymer coating compared to the standard uncoated p48 flow diverter using an in vitro thrombogenicity assay.
Methods: To evaluate the thrombin generation influenced by the different stent types the stents were placed in wells of a 24-well plate with the addition of plasma from healthy volunteers the thrombin calibrator respectively the PPP-reagent was added. Subsequently, the thrombin substrate was added and the thrombin generation was analysed every 60 s using a thrombinoscope. The assay is calibrated using samples containing a known amount of active thrombin in PPP. Thrombin activity is proportional to the change in fluorescence.
Results: The p48 hydrophilic polymer coating shows a significantly lower peak thrombin concentration (1.13 ± 0.21 vs. 1.41 ± 0.22) and longer time to peak thrombin concentration (0.96 ± 0.04 vs. 0.74 ± 0.07) compared to the uncoated p48 device ( < 0.01). The responses of the p48 hydrophilic polymer coating were similar to that of the negative control.
Conclusion: The hydrophilic polymer coating surface modification significantly reduces the thrombogenicity of the p48 flow diverter. These results corroborate the findings from previous in vitro studies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446597 | PMC |
| http://dx.doi.org/10.1177/1591019920923817 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety and efficacy of coated flow diverters in the treatment of cerebral aneurysms during single antiplatelet therapy: A multicenter study.
Interv Neuroradiol
December 2024
University of Cologne, Faculty of Medicine and University Hospital, Department of Radiology and Neuroradiology, Cologne, Germany.
Article Synopsis
- This study analyzed the safety and effectiveness of coated flow diverters (cFDs) for treating cerebral aneurysms while patients were on single antiplatelet therapy (SAPT).
- It involved 41 patients with a median age of 58, noting a low complication rate with only 5% experiencing early ischemic issues, and no complications reported after four months for most patients.
- The results suggest that using cFDs under SAPT shows a promising occlusion rate (75% complete, 89% favorable) and calls for further research through prospective trials.
Flow diversion with hydrophilic polymer coating with prasugrel as single antiplatelet therapy in the treatment of acutely ruptured intracranial aneurysms: a multicenter case series, complication and occlusion rates.
J Neurointerv Surg
August 2024
Neuroradiology, Klinikum Stuttgart Katharinenhospital, Stuttgart, Germany.
Background: This study reports a multicenter experience of using hydrophilic polymer-coated (HPC) flow diverters with prasugrel single antiplatelet therapy to treat ruptured aneurysms with subarachnoid hemorrhage (SAH).
Methods: Patients treated for intracranial aneurysms within 30 days after SAH with a p64/p48 MW HPC flow diverter were prospectively identified. Clinical presentation and outcomes, periprocedural and postprocedural complications, and degree of occlusion at follow-up were evaluated.
Flow diverter surface modifications for aneurysm treatment: A review of the mechanisms and data behind existing technologies.
Interv Neuroradiol
October 2023
Department of Neurosurgery, North Shore University Hospital, Donald and Barbara Zucker School of Medicine, Manhasset, NY, USA.
Article Synopsis
- Flow diversion (FD) is a key treatment for large, wide-necked aneurysms but requires dual antiplatelet therapy (DAPT) to manage thromboembolic risks, complicating patient care due to potential hemorrhagic and nuisance complications.
- * Newer FD technologies incorporate surface modifications for better blood compatibility, aiming to reduce clotting and potentially allow the use of a single antiplatelet drug.
- * This review addresses the molecular mechanisms and clinical data on four major flow diverters with advanced coatings to provide a comprehensive reference for neurointerventional aneurysm treatment, excluding the uncoated Balt silk device.
Early clinical experience with the p48MW HPC and p64MW HPC flow diverters in the anterior circulation aneurysm using single anti-platelet treatment.
Interv Neuroradiol
June 2022
Neuroradiological Clinic, Klinikum Stuttgart, Stuttgart, Germany.
Background: The p64MW HPC and p48MW HPC flow diverters have reduced thrombogenicity due to hydrophilic coating. The purpose of this study was to evaluate its safety and efficacy in Mongolian patients under single antiplatelet therapy (SAPT) with prasugrel.
Materials And Methods: We performed a retrospective review of patients enrolled into our prospectively maintained database to identify all patients treated with either the p48MW HPC or p64MW HPC under SAPT.
Aneurysm Treatment in Acute SAH with Hydrophilic-Coated Flow Diverters under Single-Antiplatelet Therapy: A 3-Center Experience.
AJNR Am J Neuroradiol
March 2021
From the Institute for Diagnostic and Interventional Neuroradiology (D.L., C.C., J.K.), Helios Klinikum Erfurt, Erfurt, Germany.
Background And Purpose: In certain clinical circumstances, dual-antiplatelet therapy can be problematic in patients with acute SAH. In some aneurysms, however, flow-diverting stents are the ideal therapeutic option. We report our experience with ruptured intracranial aneurysms treated with flow diverters with hydrophilic coating (p48 MW HPC and p64 MW HPC) under single-antiplatelet therapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!